Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx( ®)): a placebo-controlled randomised phase II study (PLIANT).

CONCLUSIONS: Calmangafodipir at a dose of 5 µmol/kg appears to prevent the development of oxaliplatin-induced acute and delayed CIPN without apparent influence on tumour outcomes. PMID: 29140155 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29140155?dopt=Abstract

Source: Acta Oncologica - November 15, 2017 Category: Cancer & Oncology Authors: Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, Nittve M, Näsström J Tags: Acta Oncol Source Type: research